We present the case of a 47-year-old male who underwent treatment with Dupilumab 300 mg every two weeks who developed after six months' treatment a rare cutaneous reaction such as a long-lasting cutaneous reaction at the site of dupilumab subcutaneous injection together with eosinophilia; the patient has been switched, after a 2-month wash out period, to benralizumab 30 mg since without developing adverse reactions
Dupilumab‐Associated, Long-Lasting, Late-Onset, Large Local Reaction at the Injection Site in a Patient Treated for T2 Severe Asthma: A Case Report
Luca Gammeri;Marta Liotta;Edoardo Spina;Luisa Ricciardi
2023-01-01
Abstract
We present the case of a 47-year-old male who underwent treatment with Dupilumab 300 mg every two weeks who developed after six months' treatment a rare cutaneous reaction such as a long-lasting cutaneous reaction at the site of dupilumab subcutaneous injection together with eosinophilia; the patient has been switched, after a 2-month wash out period, to benralizumab 30 mg since without developing adverse reactionsFile in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
